Benralizumab Phase 3 Trial
Cross-source consensus on Benralizumab Phase 3 Trial from 1 sources and 2 claims.
1 sources · 2 claims
Evidence quality
Other
Highlighted claims
- The correction concerns a randomized, placebo-controlled phase 3 trial comparing benralizumab with placebo for hypereosinophilic syndrome. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals
- The HTML and PDF versions of the article were updated with the corrections. — Multinational validation of the PREVENT and SCORE2 cardiovascular risk equations across 6.4 million individuals